Want to see OMDA full AI Analyst Report?
OMDA Stock Chart & Stats
$20.53
-$0.13(-0.63%)
At close: 4:00 PM EDT
$20.53
-$0.13(-0.63%)
Day’s Range― - ―
52-Week Range$10.28 - $26.92
Previous Close$18.29
Volume562.89K
Average Volume (3M)1.14M
Market Cap
$1.18B
Enterprise Value$528.90
Total Cash (Recent Filing)$211.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 06, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding59,448,505
10 Day Avg. Volume1,187,912
30 Day Avg. Volume1,136,308
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)4.01
Price to Sales (P/S)3.54
P/FCF Ratio54.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$24.60Price Target Upside19.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.26
Revenue Forecast (FY)$327.98M
Bulls Say, Bears Say
Bulls Say
Strong Revenue & Membership MomentumOmada shows durable demand and scalable contract economics: rapid top-line growth plus guidance lift reflect stronger adoption by employers and health plans. Membership >1M (+51% YoY) supports a growing recurring revenue base that can compound over multiple years through retention and expansion.
Improving Cash Generation And Debt-Free Balance SheetPositive operating and free cash flow indicate the business is transitioning from burn to self-funding, improving runway and strategic flexibility. Together with prior balance-sheet strength, this supports durable investment in product, sales and channel build without near-term refinancing risk.
Clinical Evidence And Expanded Distribution (PBMs/Partners)Broad PBM access and inclusion in major programs create durable distribution channels into commercially insured populations. Coupled with peer‑reviewed GLP‑1 care outcomes, this enhances differentiation, stickiness and bargaining power with payers over multi-year contracts and program renewals.
Bears Say
Blended Revenue Per Member Step-DownContract design that steps down billings in years 2–3 reduces blended ARPU as cohorts mature. Sustaining revenue growth therefore requires continuous high net adds or higher‑value product upsell, creating ongoing operational pressure even as unit economics per mature member improve.
Early-Stage Prescribing Channels & Multi-Vendor PBM CompetitionKey distribution and prescribing channels (Optum Rx, Employer Connect ramps) are still nascent, delaying meaningful revenue contribution. Placement in multi‑vendor PBM programs reduces exclusivity and requires sustained go-to-market investment to capture share over multiple years.
Ongoing GAAP Losses And Cash-Flow VolatilityAlthough margins and adjusted EBITDA improved, GAAP profitability remains negative and cash-flow history shows volatility. Persistent losses or inconsistent multi-year free cash flow could erode equity returns and constrain long-term reinvestment if momentum stalls.
Omada Health, Inc. News
OMDA FAQ
What was Omada Health, Inc.’s price range in the past 12 months?
Omada Health, Inc. lowest stock price was $10.28 and its highest was $26.91 in the past 12 months.
What is Omada Health, Inc.’s market cap?
Omada Health, Inc.’s market cap is $1.18B.
When is Omada Health, Inc.’s upcoming earnings report date?
Omada Health, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Omada Health, Inc.’s earnings last quarter?
Omada Health, Inc. released its earnings results on May 07, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.128 by $0.168.
Is Omada Health, Inc. overvalued?
According to Wall Street analysts Omada Health, Inc.’s price is currently Undervalued.
Does Omada Health, Inc. pay dividends?
Omada Health, Inc. does not currently pay dividends.
What is Omada Health, Inc.’s EPS estimate?
Omada Health, Inc.’s EPS estimate is 0.06.
How many shares outstanding does Omada Health, Inc. have?
Omada Health, Inc. has 59,448,505 shares outstanding.
What happened to Omada Health, Inc.’s price movement after its last earnings report?
Omada Health, Inc. reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.128. Following the earnings report the stock price went down -9.634%.
Which hedge fund is a major shareholder of Omada Health, Inc.?
Currently, no hedge funds are holding shares in OMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omada Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.60 (19.82% Upside)
$24.60 (19.82% Upside)
Blogger Sentiment
Neutral
OMDA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
114.47%
Trailing 12-Months
Company Description
Omada Health, Inc.
Omada Health is an American virtual health company that delivers evidence-based digital programs designed to manage common chronic ailments, including cardiometabolic, musculoskeletal, and behavioral health conditions, offering continuous support that bridges the gap between in-person medical appointments.
OMDA Company Deck
OMDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong growth and improving financial health: double-digit revenue growth (42% YoY), a key membership milestone (1.025M members, +51% YoY), margin expansion (GAAP 62%, non-GAAP 64%), positive adjusted EBITDA in Q1 and an upward revision to full-year guidance. Commercial momentum was highlighted by relationships with all three large PBMs and inclusion in Optum Rx and Lilly programs, alongside differentiated clinical evidence for the GLP-1 Care Track. Near-term headwinds are mostly transitional or tactical — cohort composition pressuring blended revenue per member, early-stage nature of some prescribing channels with material revenue expected more in 2027, modest device/shipping cost pressure (~$1M) and competitive multi-vendor PBM environments. Overall, the positives materially outweigh the manageable near-term challenges.View all OMDA earnings summariesOMDA Stock 12 Month Forecast
Average Price Target
$24.60
▲(19.82% Upside)
Technical Analysis
Teladoc
―
American Well
―
GoodRx Holdings
―
Privia Health Group
―
Hinge Health, Inc. Class A
―
Ownership Overview
3.73% Insiders
15.62% Mutual Funds
6.45% Other Institutional Investors
67.62% Public Companies and
Individual Investors